Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
Daniel SidlerAlexander BornSimeon SchietzelMichael P HornDaniel AeberliJennifer AmslerBurkhard MöllerLinet M NjueCesare MedriAnne Angelillo-ScherrerLuca BorradoriS Morteza Seyed JafariSusanne Radonjic-HoesliAndrew ChanRobert HoepnerUlrike BacherLaila-Yasmin ManiJoseena Mariam IypeFranziska Suter-RinikerCornelia StaehelinMichael NaglerCedric HirzelBritta MaurerMatthias B MoorPublished in: RMD open (2022)
This study reveals comparable immunity decay rates between patients with anti-CD20 treatments and healthy volunteers, but inefficient humoral or CMI after a third SARS-CoV-2 vaccine in most two-dose humoral non-responders calling for individually tailored vaccination strategies in this population.Trial registration numberNCT04877496; ClinicalTrials.gov number.